Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles

被引:34
作者
Balmelli, C
Demotz, S
Acha-Orbea, H
De Grandi, P
Nardelli-Haefliger, D
机构
[1] CHU Vaudois, Dept Gynecol, CH-1011 Lausanne, Switzerland
[2] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
[3] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
关键词
D O I
10.1128/JVI.76.24.12596-12602.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vaccination by the nasal route has been successfully used for the induction of immune responses. Either the nasal-associated lymphoid tissue (NALT), the bronchus-associated lymphoid tissue, or lung dendritic cells have been mainly involved. Following nasal vaccination of mice with human papillomavirus type 16 (HPV16) virus-like-particles (VLPs), we have previously shown that interaction of the antigen with the lower respiratory tract was necessary to induce high titers of neutralizing antibodies in genital secretions. However, following a parenteral priming, nasal vaccination with HPV16 VLPs did not require interaction with the lung to induce a mucosal immune response. To evaluate the contribution of the upper and lower respiratory tissues and associated lymph nodes (LN) in the induction of humoral responses against HPV16 VLPs after nasal vaccination, we localized the immune inductive sites and identified the antigen-presenting cells involved using a specific CD4(+) T-cell hybridoma. Our results show that the trachea, the lung, and the tracheobronchial LN were the major sites responsible for the induction of the immune response against HPV16 VLP, while the NALT only played a minor role. Altogether, our data suggest that vaccination strategies aiming to induce efficient immune responses against HPV16 VLP in the female genital tract should target the lower respiratory tract.
引用
收藏
页码:12596 / 12602
页数:7
相关论文
共 54 条
[1]   Nasal delivery of vaccines [J].
Almeida, AJ ;
Alpar, HO .
JOURNAL OF DRUG TARGETING, 1996, 3 (06) :455-467
[2]  
ASHWELL JD, 1988, J IMMUNOL, V141, P2536
[3]  
AUSTYN JM, 1998, J EXP MED, V67, P646
[4]   Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions [J].
Balmelli, C ;
Roden, R ;
Potts, A ;
Schiller, J ;
De Grandi, P ;
Nardelli-Haefliger, D .
JOURNAL OF VIROLOGY, 1998, 72 (10) :8220-8229
[5]  
BIENENSTOCK J, 1973, LAB INVEST, V28, P686
[6]  
BRANDTZAEG P, 1992, ADV OTO-RHINO-LARYNG, V47, P64
[7]  
Brandtzaeg P., 1997, ANN NY ACAD SCI, V820, P1
[8]  
Briskin M, 1997, AM J PATHOL, V151, P97
[9]   EXPRESSION OF INTERLEUKIN-2 RECEPTORS AS A DIFFERENTIATION MARKER ON INTRATHYMIC STEM-CELLS [J].
CEREDIG, R ;
LOWENTHAL, JW ;
NABHOLZ, M ;
MACDONALD, HR .
NATURE, 1985, 314 (6006) :98-100
[10]  
CHESNUT RW, 1982, J IMMUNOL, V128, P1764